LEVEL 38, MELBOURNE, VICTORIA, C3
Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
Material disclosure
.3
Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
DRAWS US$50 MILLION FROM FIVE-YEAR NON-DILUTIVE FACILITY
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis